Effects of CPAP therapy on HDL function in patienst with SAS

Effects of CPAP therapy on HDL function in patienst with SAS - CPAP and HDL functions

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025341

Enrollment

Registered

2017-01-04

Start date

2017-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep apnea syndrome

Interventions

12 weeks of CPAP therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: SAS patients with AHI 15 or greater

Exclusion criteria

Exclusion criteria: 1) HbA1c >10% 2) recent cerebrovascular events (6 months) 3) liver dysfunction (AST/ALT greater than 3 fold of upper normal limits) 4) advanced renal inssuficiency including hemodialysis 5) heart failure (NYHA III/IV) 6) cancer or critically ill patients 7) pregnant women 8) serious infection 9) subjects to whom attending doctor judges inappropriate to join the study

Design outcomes

Primary

Measure	Time frame
HDL functions	—

Secondary

Measure	Time frame
lipids and apoproteins	—

Countries

Japan

Contacts

Public ContactKatsunori Ikewaki

National Defense Medical College Division of Anti-aging and Vascular Medicine

kikewaki@hotmail.com0429-95-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026